In this 16-week , double-blind , randomized , parallel group study , 196 currently untreated subjects with mild-tomoderate AD ( Mini Mental State Examination [ MMSE ] 16-24 ) received GSK239512 ( n = 97 ) ; or placebo ( n = 99 ) administered orally each morning .